A phase I trial of flavopiridol in relapsed multiple myeloma

Craig C. Hofmeister, Ming Poi, Mindy A. Bowers, Weiqiang Zhao, Mitch A. Phelps, Don M. Benson, Eric H. Kraut, Sherif Farag, Yvonne A. Efebera, Jennifer Sexton, Thomas S. Lin, Michael Grever, John C. Byrd

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Purpose: Flavopiridol is primarily a cyclin-dependent kinase-9 inhibitor, and we performed a dose escalation trial to determine the maximum tolerated dose and safety and generate a pharmacokinetic (PK) profile. Methods: Patients with a diagnosis of relapsed myeloma after at least two prior treatments were included. Flavopiridol was administered as a bolus and then continuous infusion weekly for 4 weeks in a 6-week cycle. Results: Fifteen patients were treated at three dose levels (30 mg/m2 bolus, 30 mg/m2 CIV to 50 mg/m2 bolus, and 50 mg/m2 CIV). Cytopenias were significant, and elevated transaminases (grade 4 in 3 patients, grade 3 in 4 patients, and grade 2 in 3 patients) were noted but were transient. Diarrhea (grade 3 in 6 patients and grade 2 in 5 patients) did not lead to hospital admission. There were no confirmed partial responses although one patient with t(4;14) had a decrease in his monoclonal protein >50 % that did not persist. PK properties were similar to prior publications, and immunohistochemical staining for cyclin D1 and phospho-retinoblastoma did not predict response. Conclusions: Flavopiridol as a single agent given by bolus and then infusion caused significant diarrhea, cytopenias, and transaminase elevation but only achieved marginal responses in relapsed myeloma (ClinicalTrials.gov identifier NCT00112723).

Original languageEnglish (US)
Pages (from-to)249-257
Number of pages9
JournalCancer Chemotherapy and Pharmacology
Volume73
Issue number2
DOIs
StatePublished - Feb 2014

Fingerprint

alvocidib
Multiple Myeloma
Pharmacokinetics
Transaminases
Cyclin-Dependent Kinase 9
Cyclin D1
Diarrhea
Maximum Tolerated Dose
Retinoblastoma
Proteins

Keywords

  • Cyclin-dependent kinase inhibitor
  • Flavopiridol
  • Multiple myeloma
  • Pharmacokinetics
  • Phase 1 clinical trial

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Toxicology

Cite this

Hofmeister, C. C., Poi, M., Bowers, M. A., Zhao, W., Phelps, M. A., Benson, D. M., ... Byrd, J. C. (2014). A phase I trial of flavopiridol in relapsed multiple myeloma. Cancer Chemotherapy and Pharmacology, 73(2), 249-257. https://doi.org/10.1007/s00280-013-2347-y

A phase I trial of flavopiridol in relapsed multiple myeloma. / Hofmeister, Craig C.; Poi, Ming; Bowers, Mindy A.; Zhao, Weiqiang; Phelps, Mitch A.; Benson, Don M.; Kraut, Eric H.; Farag, Sherif; Efebera, Yvonne A.; Sexton, Jennifer; Lin, Thomas S.; Grever, Michael; Byrd, John C.

In: Cancer Chemotherapy and Pharmacology, Vol. 73, No. 2, 02.2014, p. 249-257.

Research output: Contribution to journalArticle

Hofmeister, CC, Poi, M, Bowers, MA, Zhao, W, Phelps, MA, Benson, DM, Kraut, EH, Farag, S, Efebera, YA, Sexton, J, Lin, TS, Grever, M & Byrd, JC 2014, 'A phase I trial of flavopiridol in relapsed multiple myeloma', Cancer Chemotherapy and Pharmacology, vol. 73, no. 2, pp. 249-257. https://doi.org/10.1007/s00280-013-2347-y
Hofmeister CC, Poi M, Bowers MA, Zhao W, Phelps MA, Benson DM et al. A phase I trial of flavopiridol in relapsed multiple myeloma. Cancer Chemotherapy and Pharmacology. 2014 Feb;73(2):249-257. https://doi.org/10.1007/s00280-013-2347-y
Hofmeister, Craig C. ; Poi, Ming ; Bowers, Mindy A. ; Zhao, Weiqiang ; Phelps, Mitch A. ; Benson, Don M. ; Kraut, Eric H. ; Farag, Sherif ; Efebera, Yvonne A. ; Sexton, Jennifer ; Lin, Thomas S. ; Grever, Michael ; Byrd, John C. / A phase I trial of flavopiridol in relapsed multiple myeloma. In: Cancer Chemotherapy and Pharmacology. 2014 ; Vol. 73, No. 2. pp. 249-257.
@article{12bd3f631e6a4bb69fd982fd1865fea7,
title = "A phase I trial of flavopiridol in relapsed multiple myeloma",
abstract = "Purpose: Flavopiridol is primarily a cyclin-dependent kinase-9 inhibitor, and we performed a dose escalation trial to determine the maximum tolerated dose and safety and generate a pharmacokinetic (PK) profile. Methods: Patients with a diagnosis of relapsed myeloma after at least two prior treatments were included. Flavopiridol was administered as a bolus and then continuous infusion weekly for 4 weeks in a 6-week cycle. Results: Fifteen patients were treated at three dose levels (30 mg/m2 bolus, 30 mg/m2 CIV to 50 mg/m2 bolus, and 50 mg/m2 CIV). Cytopenias were significant, and elevated transaminases (grade 4 in 3 patients, grade 3 in 4 patients, and grade 2 in 3 patients) were noted but were transient. Diarrhea (grade 3 in 6 patients and grade 2 in 5 patients) did not lead to hospital admission. There were no confirmed partial responses although one patient with t(4;14) had a decrease in his monoclonal protein >50 {\%} that did not persist. PK properties were similar to prior publications, and immunohistochemical staining for cyclin D1 and phospho-retinoblastoma did not predict response. Conclusions: Flavopiridol as a single agent given by bolus and then infusion caused significant diarrhea, cytopenias, and transaminase elevation but only achieved marginal responses in relapsed myeloma (ClinicalTrials.gov identifier NCT00112723).",
keywords = "Cyclin-dependent kinase inhibitor, Flavopiridol, Multiple myeloma, Pharmacokinetics, Phase 1 clinical trial",
author = "Hofmeister, {Craig C.} and Ming Poi and Bowers, {Mindy A.} and Weiqiang Zhao and Phelps, {Mitch A.} and Benson, {Don M.} and Kraut, {Eric H.} and Sherif Farag and Efebera, {Yvonne A.} and Jennifer Sexton and Lin, {Thomas S.} and Michael Grever and Byrd, {John C.}",
year = "2014",
month = "2",
doi = "10.1007/s00280-013-2347-y",
language = "English (US)",
volume = "73",
pages = "249--257",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - A phase I trial of flavopiridol in relapsed multiple myeloma

AU - Hofmeister, Craig C.

AU - Poi, Ming

AU - Bowers, Mindy A.

AU - Zhao, Weiqiang

AU - Phelps, Mitch A.

AU - Benson, Don M.

AU - Kraut, Eric H.

AU - Farag, Sherif

AU - Efebera, Yvonne A.

AU - Sexton, Jennifer

AU - Lin, Thomas S.

AU - Grever, Michael

AU - Byrd, John C.

PY - 2014/2

Y1 - 2014/2

N2 - Purpose: Flavopiridol is primarily a cyclin-dependent kinase-9 inhibitor, and we performed a dose escalation trial to determine the maximum tolerated dose and safety and generate a pharmacokinetic (PK) profile. Methods: Patients with a diagnosis of relapsed myeloma after at least two prior treatments were included. Flavopiridol was administered as a bolus and then continuous infusion weekly for 4 weeks in a 6-week cycle. Results: Fifteen patients were treated at three dose levels (30 mg/m2 bolus, 30 mg/m2 CIV to 50 mg/m2 bolus, and 50 mg/m2 CIV). Cytopenias were significant, and elevated transaminases (grade 4 in 3 patients, grade 3 in 4 patients, and grade 2 in 3 patients) were noted but were transient. Diarrhea (grade 3 in 6 patients and grade 2 in 5 patients) did not lead to hospital admission. There were no confirmed partial responses although one patient with t(4;14) had a decrease in his monoclonal protein >50 % that did not persist. PK properties were similar to prior publications, and immunohistochemical staining for cyclin D1 and phospho-retinoblastoma did not predict response. Conclusions: Flavopiridol as a single agent given by bolus and then infusion caused significant diarrhea, cytopenias, and transaminase elevation but only achieved marginal responses in relapsed myeloma (ClinicalTrials.gov identifier NCT00112723).

AB - Purpose: Flavopiridol is primarily a cyclin-dependent kinase-9 inhibitor, and we performed a dose escalation trial to determine the maximum tolerated dose and safety and generate a pharmacokinetic (PK) profile. Methods: Patients with a diagnosis of relapsed myeloma after at least two prior treatments were included. Flavopiridol was administered as a bolus and then continuous infusion weekly for 4 weeks in a 6-week cycle. Results: Fifteen patients were treated at three dose levels (30 mg/m2 bolus, 30 mg/m2 CIV to 50 mg/m2 bolus, and 50 mg/m2 CIV). Cytopenias were significant, and elevated transaminases (grade 4 in 3 patients, grade 3 in 4 patients, and grade 2 in 3 patients) were noted but were transient. Diarrhea (grade 3 in 6 patients and grade 2 in 5 patients) did not lead to hospital admission. There were no confirmed partial responses although one patient with t(4;14) had a decrease in his monoclonal protein >50 % that did not persist. PK properties were similar to prior publications, and immunohistochemical staining for cyclin D1 and phospho-retinoblastoma did not predict response. Conclusions: Flavopiridol as a single agent given by bolus and then infusion caused significant diarrhea, cytopenias, and transaminase elevation but only achieved marginal responses in relapsed myeloma (ClinicalTrials.gov identifier NCT00112723).

KW - Cyclin-dependent kinase inhibitor

KW - Flavopiridol

KW - Multiple myeloma

KW - Pharmacokinetics

KW - Phase 1 clinical trial

UR - http://www.scopus.com/inward/record.url?scp=84896040809&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896040809&partnerID=8YFLogxK

U2 - 10.1007/s00280-013-2347-y

DO - 10.1007/s00280-013-2347-y

M3 - Article

C2 - 24241210

AN - SCOPUS:84896040809

VL - 73

SP - 249

EP - 257

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 2

ER -